Paolo Pucci was appointed to the Board of Directors in November 2015. He is chief executive officer and a director of ArQule Inc., a clinical-stage biotechnology company that is researching and developing cancer therapeutics. Prior to ArQule, Paolo was senior vice president of the Bayer-Schering Pharmaceuticals Global Oncology/Specialized Therapeutics Business Unit at Bayer AG. He also served as an independent director of Dyax Corporation, until it was acquired by Shire Plc, and as an independent director of Algeta ASA, until it was acquired by Bayer AG. Paolo holds an MBA from the University of Chicago Booth School of Business and is a graduate of the Università Degli Studi di Napoli Federico II in Naples, Italy.